eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 69
 
Share:
Share:
more
 
 
abstract:
Original paper

Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole – tissue sections

Aydan Kılıçarslan, Hayriye Tatli Dogan, Nuran Süngü, Mehmet Dogan, Abdussamet Yalcin, Didem Şener Dede

Pol J Pathol 2018; 69 (2): 143-149
Online publish date: 2018/07/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The human epidermal growth factor receptor 2 (Her2/neu) signal pathway plays a significant role in the occurance of various solid tumor types. The rate of Her2/neu in colorectal carcinoma (CRC) is not clearly elucidated. In this study, we discuss the association between Her2/neu overexpression and clinicopathological parameters in CRC. Her2/neu immunohistochemical (IHC) staining was performed on whole sections of formalin fixed paraffin embedded tumor tissues of 100 CRC resections. Cases with score 3+ and score 2+ expressions were further evaluated by silver in-situ hybridization (ISH) for the existence of Her2/neu gene amplification. Her2/neu membranous overexpression was observed in 12 of the 100 cases (6 cases with a score 3+ and 6 cases with a score 2+) and 6 of these were heterogenous. There were 10 cases with Her2/neu amplification (6/6 score 3+, 4/6 score 2+). Strong cytoplasmic staining was observed in 5 cases. Membranous scores were either 3+ or 2+ in 3 of these 5 cases. Moreover, there was Her2/neu amplification in 2 of these 3 cases. Her2/neu amplification status and overexpression was not related to clinicopathological parameters and overall survival. More clear results can be obtained from studies with Her2/neu IHC and ISH test on whole sections.
keywords:

colorectal cancer, Her2/neu, immunohistochemistry, in situ hybridization

references:
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386.
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
Gutierrez C, Schiff R. HER2 biology, detection and clinical implications. Arch Pathol Lab Med 2011; 135: 55-62.
Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network. receptor heterodimerization in development and cancer. Embo J 2000; 19: 3159-3167.
Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer. prognostic value. Breast Cancer Res Treat 1998; 51: 109-119.
Bernhard H, Salazar L, Schiffman K, et al. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 2002; 9: 33-44.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
Ieni A, Barresi V, Rigoli L, et al. HER2 Status in premalignant, early, and advanced neoplastic lesions of the stomach. Dis Markers 2015; 2015: 234851.
Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014; 111: 1977-1984.
Lim SW, Kim HR, Kim HY, et al. Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cell Oncol (Dordr) 2013; 36: 311-321.
Demirbas S, Sucullu I, Yildirim S, et al. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer. Turk J Gastroenterol 2006; 17: 13-19.
Kavanagh DO, Chambers G, O’Grady L, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009; 9: 1.
Rossi HA, Liu Q, Banner B, et al. The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J 2002; 8: 268-275.
Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004; 22: 858-865.
Half E, Broaddus R, Danenberg KD, et al HER-2 receptor expression, localization and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004; 108: 540-548.
Kruszewski WJ, Rzepko R, Ciesielski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers 2010; 29: 207-212.
Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 2006; 12 : 229-236.
Kim JY, Lim SJ, Park K. Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays. Appl Immunohistochem Mol Morphol 2004; 12: 67-70.
Li Q, Wang D, Li J, et al. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011; 11: 277.
Park DI, Kang MS, Oh SJ, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007; 22: 491-497.
Uner A, Ebinc FA, Akyurek N, et al. Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol 2005; 27: 225-228.
Pyo JS, Kang G, Park K. Clinicopathological significance and diagnostic accuracy of HER2 immnohistochemistry in colorectal cancer: a meta-analysis. Int Biol Markers 2016; 31: e389-e394.
Tavangar SM, Shariftabrizi A, Soroush AR. Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients. Med Sci Monit 2005; 11: Cr123-126.
Wu SW, Ma CC, Yang Y. The prognostic value of Her-2/neu overexpression in colorectal cancer: evidence from 16 studies. Tumour Biol 2014; 35: 10799-10804.
Song Z, Deng Y, Zhuang K, et al. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol 2014; 7: 4454-4460.
Marx AH, Burandt EC, Choschzick M, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010; 41: 1577-1585.
Drecoll E, Nitsche U, Bauer K, et al. Expression analysis of heat shockprotein 90 (HSP90) and Her2 in colon carcinoma. Int J Colorectal Dis 2014; 29: 663-671.
Wu SW, Ma CC, Li WH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol 2015; 10: 144.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
McIntire M, Redston M. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. Arch Pathol Lab Med 2012; 136: 496-503.
Ciardiello F, Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab. a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov 2011; 1: 472-474.
Bang YJ, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
Sartore-Bianchi A, Trusoline L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAScodon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738-746.
Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93: 1141-1146.
Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523.
Fuchs EM, Köstler WJ, Horvat R, et al. High-level ERBB’ gene amplification is associated with a particulary short time-to-metastasis, but result in high rate of complete response once trantuzumab-based therapy is offered in the metastatic setting. Int J Cancer 2014; 135: 224-231.
Josef R, Wedad H, Michael B, et al. HER2 testing in gastric cancer: a partical approach. Modern Pathology 2012; 25: 637-650.
Long TH, Lawce H, Durum C, et al. The New Equivocal. Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines. Am J Clin Pathol 2015; 144: 253-262.
Lee AH, Key HP, Bell JA, et al. The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation. J Clin Pathol 2014; 67: 573-575.
Tong LC, Nelson N, Tsourigiannis J, et al. The effect of prolonged fixatiom on the imminihistochemical evaluation of estrogen receptor, progestrone receptor, and HER2 expression in invasive est cancer: a prospective study. Am J Surg Pathol 2011; 35: 545-552.
Dursun A, Poyraz A, Suer O, et al. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res 2001; 7: 24-27.
Tu J, Yu Y, Liu W, et al. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med 2015; 9: 17-24.
Nathanson DR, Culliford ATt, Shia J, et al. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003; 105: 796-802.
Blok EJ, Kuppen PJ, van Leeuwen JE, et al. Cytoplasmic overexpression of HER2. a key factor in colorectal cancer. Clin Med Insights Oncol 2013; 7: 41-51.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe